| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2039985 | Cell Reports | 2016 | 7 Pages |
•Neutralization studies with convalescent ZIKV-immune sera identify a single serotype•Infection with a single ZIKV strain elicits broadly neutralizing antibodies•Strain selection may not be a critical parameter for ZIKV vaccine development
SummaryRecent epidemics of Zika virus (ZIKV) have been associated with congenital malformation during pregnancy and Guillain-Barré syndrome. There are two ZIKV lineages (African and Asian) that share >95% amino acid identity. Little is known regarding the ability of neutralizing antibodies elicited against one lineage to protect against the other. We investigated the breadth of the neutralizing antibody response following ZIKV infection by measuring the sensitivity of six ZIKV strains to neutralization by ZIKV-confirmed convalescent human serum or plasma samples. Contemporary Asian and early African ZIKV strains were similarly sensitive to neutralization regardless of the cellular source of virus. Furthermore, mouse immune serum generated after infection with African or Asian ZIKV strains was capable of neutralizing homologous and heterologous ZIKV strains equivalently. Because our study only defines a single ZIKV serotype, vaccine candidates eliciting robust neutralizing antibody responses should inhibit infection of both ZIKV lineages, including strains circulating in the Americas.
Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slide
